Case Report
Schizoaffective Disorder in an Individual with Mowat-Wilson Syndrome (MWS)
Yadwinder Chuhan, Nimrit Bath and Muhammad Ayub*
Published: 31 January, 2024 | Volume 8 - Issue 1 | Pages: 008-011
Mowat-Wilson Syndrome (MWS) is an autosomal dominant genetic syndrome caused by mutations in the ZEB2 gene. It is characterized by distinctive facial appearance, intellectual disability (ID), epilepsy, Hirschsprung disease (HSCR), and other congenital anomalies. The psychiatric symptoms, associated with MWS have rarely been reported. The following report highlights a case of schizoaffective disorder in a 24-year-old male with MWS and the challenges he encountered over his treatment course.
After considering numerous diagnoses including bipolar disorder and psychosis secondary to a general medical condition, the patient was diagnosed with schizoaffective disorder. Various trials consisting of atypical antipsychotics and mood stabilizers were unsuccessful in managing his symptoms. Eventually, the patient stabilized on a medication regimen consisting of clozapine 300 mg once daily, topiramate 75 mg twice per day, and lithium 1800 mg once daily.
This case report documents co-occurrence of MWS and Schizoaffective disorder.
Read Full Article HTML
DOI: 10.29328/journal.apmh.1001050
Cite this Article
Read Full Article PDF
Keywords:
Mowat-Wilson Syndrome; Intellectual disability; Schizoaffective disorder; Treatment resistance
References
- Garavelli L, Mainardi PC. Mowat-Wilson syndrome. Orphanet J Rare Dis. 2007 Oct 24;2:42. doi: 10.1186/1750-1172-2-42. PMID: 17958891; PMCID: PMC2174447.
- Ivanovski I, Djuric O, Caraffi SG, Santodirocco D, Pollazzon M, Rosato S, Cordelli DM, Abdalla E, Accorsi P, Adam MP, Ajmone PF, Badura-Stronka M, Baldo C, Baldi M, Bayat A, Bigoni S, Bonvicini F, Breckpot J, Callewaert B, et al. Phenotype and genotype of 87 patients with Mowat-Wilson syndrome and recommendations for care. Genet Med. 2018 Sep;20(9):965-975. doi: 10.1038/gim.2017.221. Epub 2018 Jan 4. PMID: 29300384.
- Jakubiak A, Szczałuba K, Badura-Stronka M, Kutkowska-Kaźmierczak A, Jakubiuk-Tomaszuk A, Chilarska T, Pilch J, Braun-Walicka N, Castaneda J, Wołyńska K, Wiśniewska M, Kugaudo M, Bielecka M, Pesz K, Wierzba J, Latos-Bieleńska A, Obersztyn E, Krajewska-Walasek M, Śmigiel R. Clinical characteristics of Polish patients with molecularly confirmed Mowat-Wilson syndrome. J Appl Genet. 2021 Sep;62(3):477-485. doi: 10.1007/s13353-021-00636-1. Epub 2021 May 12. PMID: 33982229; PMCID: PMC8357696.
- Ricci E, Fetta A, Garavelli L, Caraffi S, Ivanovski I, Bonanni P, Accorsi P, Giordano L, Pantaleoni C, Romeo A, Arena A, Bonetti S, Boni A, Chiarello D, Di Pisa V, Epifanio R, Faravelli F, Finardi E, Fiumara A, Grioni D, Mammi I, Negrin S, Osanni E, Raviglione F, Rivieri F, Rizzi R, Savasta S, Tarani L, Zanotta N; Mowat Wilson Epilepsy Study Group; Dormi A, Vignoli A, Canevini M, Cordelli DM. Further delineation and long-term evolution of electroclinical phenotype in Mowat Wilson Syndrome. A longitudinal study in 40 individuals. Epilepsy Behav. 2021 Oct 4;124:108315. doi: 10.1016/j.yebeh.2021.108315. Epub ahead of print. PMID: 34619538.
- Evans E, Einfeld S, Mowat D, Taffe J, Tonge B, Wilson M. The behavioral phenotype of Mowat-Wilson syndrome. Am J Med Genet A. 2012 Feb;158A(2):358-66. doi: 10.1002/ajmg.a.34405. Epub 2012 Jan 13. PMID: 22246645.
- American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders: DSM-5, 5th ed. American Psychiatric Publishing, Washington, D.C.
- Besterman AD, Hendren RL. Psychopharmacological Management of Problem Behaviors in Mowat-Wilson Syndrome. J Child Adolesc Psychopharmacol. 2015 Oct;25(8):656-7. doi: 10.1089/cap.2015.0107. Epub 2015 Sep 24. PMID: 26402313; PMCID: PMC4615772.
- de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016 Oct 3;16(1):341. doi: 10.1186/s12888-016-1049-5. PMID: 27716110; PMCID: PMC5048618.
- Correll CU, Maayan L, Kane J, Hert MD, Cohen D. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry. 2016 Jun;77(6):e746-56. doi: 10.4088/JCP.15r10373. PMID: 27337425.
- Dykens EM, Shah B, Davis B, Baker C, Fife T, Fitzpatrick J. Psychiatric disorders in adolescents and young adults with Down syndrome and other intellectual disabilities. J Neurodev Disord. 2015;7(1):9. doi: 10.1186/s11689-015-9101-1. Epub 2015 Mar 1. PMID: 25810793; PMCID: PMC4373108.
- Owen MJ, O'Donovan MC. Schizophrenia and the neurodevelopmental continuum:evidence from genomics. World Psychiatry. 2017 Oct;16(3):227-235. doi: 10.1002/wps.20440. PMID: 28941101; PMCID: PMC5608820.
- Garavelli L, Ivanovski I, Caraffi SG, Santodirocco D, Pollazzon M, Cordelli DM, Abdalla E, Accorsi P, Adam MP, Baldo C, Bayat A, Belligni E, Bonvicini F, Breckpot J, Callewaert B, Cocchi G, Cuturilo G, Devriendt K, Dinulos MB, et al. Neuroimaging findings in Mowat-Wilson syndrome: a study of 54 patients. Genet Med. 2017 Jun;19(6):691-700. doi: 10.1038/gim.2016.176. Epub 2016 Nov 10. PMID: 27831545; PMCID: PMC5438871.
- Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, Detyniecki K. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017 Nov;76:24-31. doi: 10.1016/j.yebeh.2017.08.039. Epub 2017 Sep 18. PMID: 28931473.
- Rohde C, Hilker R, Siskind D, Nielsen J. Real-world effectiveness of clozapine for intellectual disability: Results from a mirror-image and a reverse-mirror-image study. J Psychopharmacol. 2018 Nov;32(11):1197-1203. doi: 10.1177/0269881118783322. Epub 2018 Jun 26. PMID: 29944071.
- Rothärmel M, Szymoniak F, Pollet C, Beherec L, Quesada P, Leclerc S, Belhaine A, Rosier A, Guillin O. Eleven Years of Clozapine Experience in Autism Spectrum Disorder: Efficacy and Tolerance. J Clin Psychopharmacol. 2018 Dec;38(6):577-581. doi: 10.1097/JCP.0000000000000955. PMID: 30285998.
Figures: